e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Circulating fibrocytes as a new tool to predict lung cancer progression after surgery?
Pauline Henrot, Fabien Beaufils, Matthieu Thumerel, Edmée Eyraud, Augustin Boudoussier, Hugues Begueret, Elise Maurat, Pierre-Olivier Girodet, Roger Marthan, Patrick Berger, Isabelle Dupin, Maéva Zysman
Source:
Eur Respir J, 58 (6) 2101221; 10.1183/13993003.01221-2021
Journal Issue:
December
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Pauline Henrot, Fabien Beaufils, Matthieu Thumerel, Edmée Eyraud, Augustin Boudoussier, Hugues Begueret, Elise Maurat, Pierre-Olivier Girodet, Roger Marthan, Patrick Berger, Isabelle Dupin, Maéva Zysman. Circulating fibrocytes as a new tool to predict lung cancer progression after surgery?. Eur Respir J, 58 (6) 2101221; 10.1183/13993003.01221-2021
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Markers of angiogenesis in serum are correlating with disease progress in lung cancer
Source: Annual Congress 2006 - Prognostic factors in lung cancer
Year: 2006
Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients?
Source: Eur Respir J 2015; 46: 1548-1550
Year: 2015
Issues other than tissue: non-invasive biomarkers of early stage lung cancer
Source: Virtual Congress 2020 – Will the pulmonologist still play a role in the management of screen-detected pulmonary nodules?
Year: 2020
Elevation of circulating endothelial cell levels in lung cancer – a new prognostic and/or predictive marker?
Source: Annual Congress 2008 - Diagnosis and prognosis in thoracic oncology
Year: 2008
Can high levels of serum tumor markers be useful in predicting the histologic type of lung cancer?
Source: Eur Respir J 2004; 24: Suppl. 48, 77s
Year: 2004
Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019
Are serum leptin levels a prognostic factor in advanced lung cancer?
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma?
Source: Eur Respir J 2014; 43: 1240-1242
Year: 2014
Role of biomarkers for early detection of lung cancer and chemoprevention
Source: Eur Respir J 2002; 19: 1151-1158
Year: 2002
The value of adiponectin as an inflammatory marker in lung cancer?
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Evolution in the diagnostic approach to lung cancer
Source: Virtual Congress 2021 – COVID-19 and management of lung cancer
Year: 2021
Novel aspects in lung cancer pathology: how does it help for selecting chemotherapy?
Source: Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician
Year: 2010
Why can initial treatment of localised lung cancer fail?
Source: Annual Congress 2007 - Recurrence of lung cancer following resection with curative intent
Year: 2007
Serum angiopoietins as a clinical marker for resected early lung cancer
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008
The invasive diagnostics of lung cancer with secondary inflammatory changes
Source: Eur Respir J 2006; 28: Suppl. 50, 81s
Year: 2006
Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease
Source: ERJ Open Res, 6 (4) 00481-2020; 10.1183/23120541.00481-2020
Year: 2020
Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service
Source: International Congress 2018 – Genetics in chronic pulmonary diseases
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept